Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Vaccines
•
Allergy & Immunology
Do you consider immunoglobulin replacement in a patient who has rapidly waning vaccine titers but does appropriately respond to revaccination?
Related Questions
Do mRNA vaccines lead to increased rates of acute/chronic urticaria?
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
How long do you counsel patients to wait after rituximab therapy before getting live vaccines?
Do patients with a PEG allergy have a contraindication to receiving mRNA vaccines?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Why are influenza and COVID vaccines still recommended for patients on immunoglobulin replacement therapy?
How do you decide when to add a second biologic agent to a patient’s asthma treatment who has either not responded or had a partial response to dupilumab, omalizumab, mepolizumab, or tezepelumab?
For which patients could you consider direct oral amoxicillin challenge as opposed to skin testing for penicillin allergy de-labeling?
How do you manage recurrent epistaxis from nasal steroids?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
